| Literature DB >> 20976289 |
Helen Bygrave1, Katharina Kranzer, Katherine Hilderbrand, Jonathan Whittall, Guillaume Jouquet, Eric Goemaere, Nathalie Vlahakis, Laura Triviño, Lipontso Makakole, Nathan Ford.
Abstract
BACKGROUND: The provision of antiretroviral therapy (ART) to migrant populations raises particular challenges with respect to ensuring adequate treatment support, adherence, and retention in care. We assessed rates of loss to follow-up for migrant workers compared with non-migrant workers in a routine treatment programme in Morjia, Lesotho.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20976289 PMCID: PMC2951905 DOI: 10.1371/journal.pone.0013198
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Cumulative hazard estimate for being lost to follow up.
Characteristics of migrant and non-migrant patients attending ART services.
| Total patients (n = 1185) | Migrant (n = 148) | Non-migrant (n = 1,037) | p-value | ||
| CD4, median (IQR) | 211 (119–284) | 205 (94–297) | 212 (120–284) | 0.70 | |
| Sex, n (%) | Female | 798 (67%) | 66 (45%) | 732 (70.6%) | <0.0001 |
| Male | 387 (33%) | 82 (55%) | 305 (29.4%) | ||
| Age, median (IQR) | 39.1 (29.5–48.2) | 36.1 (29.6–45.9) | 39.2 (31.1–49.7) | 0.03 | |
| Pregnant at initiation | Yes | 82 (11.6) | 3 (4.6%) | 79 (10.8%) | <0.0001 |
| No | 653 (88.4%) | 63 (95.4%) | 653 (89.2%) | ||
| TB at initiation | Yes | 198 (16.7%) | 198 (16.7%) | 168 (16.2%) | 0.21 |
| No | 987 (83.3%) | 118 (79.7%) | 869 (83.8%) | ||
| Baseline Regimen | Tenofovir | 607 (51.2%) | 100 (67.6%) | 507 (48.9%) | <0.0001 |
| Zidovudine | 266 (22.5%) | 21 (14.2%) | 245 (23.6%) | ||
| Stavudine | 312 (26.3%) | 27 (18.2%) | 285 (27.5%) |
*data missing for 48 patients.
**denominator includes only women.
Multivariate analysis of rate of loss to follow up at different time points comparing migrants to non-migrants.
| Time on antiretroviral therapy | |||||||||||
| <6 weeks(n = 1137) | 6 weeks–3 months(n = 1089) | 3–6 months(n = 1055) | 6–12 months(n = 1011) | >12 months(n = 921) | |||||||
| Adjusted Rate Ratio (95%CI) | p-value | Adjusted Rate Ratio (95%CI) | p-value | Adjusted Rate Ratio (95%CI) | p-value | Adjusted Rate Ratio (95%CI) | p-value | Adjusted Rate Ratio (95%CI) | p-value | ||
| Migrant | No | 1 | 1 | 1 | 1 | 1 | |||||
| Yes | 0.64 (0.08–4.92) | 0.67 | 1.37 (0.30–6.31) | 0.69 | 2.78 (1.15–6.73) | 0.02 | 2.36 (1.18–4.73) | 0.02 | 6.69 (3.18–14.09) | <0.01 | |
| Sex | Female | 1 | 1 | 1 | 1 | 1 | |||||
| Male | 0.28 (0.06–1.27) | 0.90 | 0.95 (0.84–1.07) | 0.36 | 0.87 (0.78–0.96) | 0.01 | 1.06 (0.56–2.00) | 0.85 | 0.37 (0.15–0.93) | 0.04 | |
| Age | <40 years | 1 | 1 | 1 | 1 | 1 | |||||
| >40 years | 0.99 (0.90–1.10) | 0.10 | 0.51 (0.14–1.92) | 0.32 | 0.88 (0.37–2.08) | 0.77 | 0.93 (0.87–0.99) | 0.02 | 0.93 (0.85–1.10) | 0.07 | |
| CD4 at initiation | ≤200 cells/mm3 | 1 | 1 | 1 | 1 | 1 | |||||
| >200 cells/mm3 | 0.29 (0.10–0.85) | 0.02 | 0.46 (0.15–1.44) | 0.18 | 0.75 (0.34–1.68) | 0.49 | 0.72 (0.39–1.34) | 0.30 | 0.81 (0.39–1.71) | 0.58 | |
| TB at initiation | No | 1 | 1 | 1 | 1 | 1 | |||||
| Yes | 0.31 (0.04–2.39) | 0.26 | 1.35 (0.36–5.09) | 0.65 | 0.61 (0.18–2.11) | 0.44 | 2.03 (1.03–3.99) | 0.04 | 1.96 (0.81–4.71) | 0.13 | |
All variables adjusted for in the final analysis.
*Baseline CD4 counts missing for 48 patients.